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Abstract. 
 
Smac/DIABLO, a recently identiﬁed inhibitor
of apoptosis protein (IAP)-binding protein, is released
from the mitochondria during apoptosis and reportedly
potentiates apoptosis by relieving the inhibition of IAPs
on caspases. We now describe the molecular character-
ization of Smac 
 
b
 
, an alternatively spliced form of Smac,
which lacks the mitochondrial-targeting sequence found
in Smac and has a cortical distribution in both human
embryonic kidney 293 and breast epithelial tumor MCF-7
cells. Smac 
 
b
 
, which binds IAPs in vitro, does not bind
IAPs in intact cells due to cellular processing and re-
moval of its NH
 
2
 
-terminal IAP-binding domain. Despite
its inability to interact with IAPs in cells, processed Smac
 
b
 
 is proapoptotic, as demonstrated by its ability to po-
tentiate apoptosis induced by both death receptor and
chemical stimuli. Furthermore, expression of a NH
 
2
 
-
terminally truncated Smac mutant (
 
D
 
75), which lacks
the entire IAP-interacting domain, potentiates apop-
tosis to the same extent as Smac and Smac 
 
b
 
. Our data
support the hypothesis that the main proapoptotic
function of Smac and Smac 
 
b
 
 is due to a mechanism
other than IAP binding.
Key words: TRAIL • XIAP • alternative splicing •
MCF-7 cells • mitochondria
 
Introduction
 
Apoptosis is an essential mechanism of cell death required
for the correct development and homeostasis of multicellu-
lar organisms. Two major apoptotic pathways have been
identified: (a) triggering of cell surface death receptors of
the tumor necrosis factor (TNF)
 
1
 
 receptor superfamily, in-
cluding TNF
 
a
 
, CD95 (Fas/Apo-1), and TNF-related apop-
tosis-inducing ligand (TRAIL), where caspase-8 is activated
following its recruitment to a trimerized receptor–ligand
complex via adaptor molecules (for reviews see Ashkenazi
and Dixit, 1999; Bratton et al., 2000), and (b) stress-induced
apoptosis, caused by chemicals and growth factor depriva-
tion, which results in perturbation of mitochondria and the
ensuing release of proteins, such as cytochrome 
 
c,
 
 from the
intermitochondrial membrane space (Green and Reed,
1998; Bratton et al., 2000)
 
.
 
 Released cytochrome 
 
c
 
 binds to
the human CED4 homologue Apaf-1 (Zou et al., 1997),
which in the presence of dATP, results in the recruitment
and activation of caspase-9 (Li et al., 1997; Cain et al.,
1999; Zou et al., 1999). The release of cytochrome 
 
c
 
 from
the mitochondria is also regulated partly by Bcl-2 family
members with antiapoptotic and proapoptotic members
inhibiting or promoting the release, respectively (Kluck et
al., 1997; Yang et al., 1997; Li et al., 1998; Luo et al., 1998).
The activated initiator caspases-8 and -9 then activate the
effector caspases-3, -6, and -7, which are responsible for
the cleavage of important cellular substrates, resulting in
the classical biochemical and morphological changes as-
sociated with the apoptotic phenotype (Cohen, 1997;
Earnshaw et al., 1999).
Caspase activity is also regulated by the inhibitor of
apoptosis proteins (IAPs), which are found in a range of
organisms and are characterized by one or more baculovirus
IAP repeats, which are responsible for their antiapoptotic ac-
tivity (for reviews see Deveraux et al., 1997; Deveraux and
Reed, 1999). One major function of IAPs, particularly
c-IAP-1 and -2 and X-linked IAP (XIAP), is their pro-
pensity to bind to and inhibit key initiator and effector
caspases including caspases-9, -3, and -7 (Deveraux et
al., 1997; Deveraux and Reed, 1999).
Recently, a novel protein, Smac, and its murine homo-
logue, DIABLO, were described, which promoted caspase
activation by eliminating IAP inhibition of caspases (Du et
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al., 2000; Verhagen et al., 2000). Smac is synthesized as a
239–amino acid precursor protein, with the NH
 
2
 
-terminal
55 amino acids serving as a mitochondrial-targeting signal.
In response to apoptotic stimuli, mature Smac is released
into the cytoplasm. In vitro, mature Smac binds all known
human IAP family members and relieves their inhibition
of caspases. Recently, this interaction has been mapped to
the NH
 
2
 
-terminal 20 amino acids of the mature Smac pro-
tein, and removal of this region completely blocks its abil-
ity to bind XIAP (Chai et al., 2000; Srinivasula et al.,
2000). Because Smac acts to prevent IAP activity, it is pro-
posed to be a human equivalent of the 
 
Drosophila
 
 pro-
teins Reaper, Grim, and Hid (Du et al., 2000; Verhagen et
al., 2000).
In this study, we describe Smac 
 
b
 
, an alternatively
spliced form of Smac, which lacks the mitochondrial-tar-
geting sequence and has a cortical as apposed to a mito-
chondrial subcellular distribution. Both Smac 
 
b
 
 and trun-
cated forms of Smac that lack the IAP interacting domain,
markedly potentiate apoptosis induced by diverse apop-
totic stimuli
 
.
 
 These data demonstrate that the main proap-
optotic function of Smac and Smac 
 
b
 
 is not mediated
through an interaction with the IAPs.
 
Materials and Methods
 
Materials
 
Medium and serum were purchased from Life Technologies. c-IAP-1 and
-2 polyclonal antibodies were from R&D Systems, and XIAP and herpes
simplex virus (HSV) monoclonal antibodies were from BD Transduction
Labs and Novagen, respectively. The HRP-conjugated secondary antibod-
ies, goat anti–rabbit and goat anti–mouse, were from Dako and Sigma-
Aldrich, respectively. Anti–mouse Alexa 488 and MitoTracker™ red
CMXRos were from Molecular Probes. Carbobenzoxyl-leucinyl-leucinyl-
leucinal (MG132) was obtained from Calbiochem. TRAIL was produced
as described previously (MacFarlane et al., 1997a). Unless stated other-
wise, all other chemicals were from Sigma-Aldrich.
 
Generation of Constructs
 
All Smac and Smac 
 
b
 
 constructs were generated by PCR amplification
and cloned into the expression vector pTriEx-1 (Novagen). Total RNA
was isolated using TriReagent and reverse transcribed using Expand™ re-
verse transcriptase (Roche Diagnostics) before amplification of full-
length Smac and Smac 
 
b
 
 cDNA using 
 
Pfu
 
 DNA polymerase (Stratagene).
Deletion mutants were generated in the same manner, and all constructs
were verified by DNA sequencing.
 
Cell Culture, Transfection, and Induction of Cell Death
 
Human embryonic kidney 293 cells were obtained from the European Col-
lection of Animal Cell Cultures and grown in high glucose DME supple-
mented with 10% FBS. MCF-7-Fas (MCF-7) human breast epithelial cells
(from Dr. M. Jaattela, Danish Cancer Society Research Center, Copen-
hagen, Denmark) were grown in RPMI 1640 supplemented with 10% FBS
and 2 mM Glutamax™. Both cell lines were cultured in an atmosphere of
5% CO
 
2 
 
in air at 37
 
8
 
C and maintained by routine passage every 3–4 d.
Cells were transiently transfected using Fugene 6™ (Roche Biochemicals)
and 0.5–4 
 
m
 
g DNA, where indicated in the presence of pRSC 
 
lacZ
 
 (Mac-
Farlane et al., 1997a). After 24 h, cells were either harvested or exposed to
an apoptotic stimulus. Apoptosis was induced by treatment for 6 h with ei-
ther etoposide, MG132, TNF (in the presence or absence of cyclohexim-
ide), or TRAIL. The extent of apoptosis was assessed by counting the per-
centage of apoptotic blue- (
 
b
 
-galactosidase–expressing) transfected cells.
 
Immunofluorescence Microscopy
 
Cells were grown on coverslips and 24 h after transfection, stained with
MitoTracker™ (100 nM) for 15 min at 37
 
8
 
C before fixation in 3.8% form-
aldehyde for 20 min at room temperature. Cells were rinsed three times in
PBS, permeablized with 0.1% Triton X-100 in PBS and blocked overnight
in 3% BSA in PBS at 4
 
8
 
C. Cells were incubated with HSV antibody
(1:25,000 in 3% BSA) for 3 h at room temperature and then incubated
with anti–mouse Alexa 488 (1:300) for 45 min at room temperature. The
cells were then washed and nuclei were stained with Hoechst 33258 (0.25
 
m
 
g/ml) for 20 min before mounting onto glass slides using Vectashield
 
®
 
(Vector Laboratories). Optical sections were taken using argon-krypton,
UV lasers, and a Leica TCS-4D confocal imaging system.
 
Production of Recombinant Proteins
 
Recombinant proteins were produced in 
 
Escherichia coli
 
 BL21(DE3) as
described previously (Zou et al., 1997) and retained on beads. The puri-
fied proteins were stored in aliquots at 4
 
8
 
C, and their identity was con-
firmed by Western blotting using anti-HSV monoclonal antibody.
 
Production of 
 
35
 
S-labeled Proteins and In Vitro 
Interaction Assay
 
35
 
S-labeled proteins were produced using the TNT
 
®
 
-coupled reticulocyte
lysate system (Promega). The constructs used were pcDNA3 human
MIHB (c-IAP-1), human MIHC (c-IAP-2), and pSP72 XIAP (gifts from
Dr. D. Vaux, The Walter and Eliza Hall Institute, Melbourne, Australia).
For the in vitro interaction assay, 10 
 
m
 
l of Ni-NTA agarose beads
(QIAGEN) or beads bound to recombinant protein were added to 5 
 
m
 
l of
TNT mix, and the final volume was adjusted to 100 
 
m
 
l with buffer A (50
mM Tris, 150 mM NaCl, 0.1% IGEPAL CA-630, pH 7.6), before incuba-
tion for 1 h at room temperature. The beads were then pelleted, washed in
buffer A, and resuspended in SDS-PAGE sample buffer before resolving
on a 13% SDS–polyacrylamide gel. As a marker, 1 
 
m
 
l of the TNT reaction
was run alongside the beads. The gel was then dried and visualized by au-
toradiography.
 
Immunoprecipitation Studies
 
Cells were harvested 24 h after transfection, and immunoprecipitation of
XIAP was carried out as described previously (Srinivasula et al., 1997). To
precipitate Smac and Smac 
 
b
 
 via the His
 
6
 
 tag, lysates were prepared and
incubated overnight with Ni-NTA agarose beads at 4
 
8
 
C and then washed
and prepared for SDS-PAGE.
 
Gel Electrophoresis and Western Blotting
 
Equal amounts of lysate were diluted in SDS-PAGE sample buffer and
separated on 13% (HSV) or 10% (XIAP and c-IAP-1 and -2) polyacryl-
amide gels followed by electrophoretic transfer onto polyvinylidene diflu-
oride membrane (Bio-Rad Laboratories). Immunodetection was carried
out as described previously (MacFarlane et al., 1997b) using ECL detec-
tion (Amersham-Pharmacia Biotech). 
 
Results and Discussion
 
Identification of Smac 
 
b
 
The protein sequence of Smac was used to search the hu-
man ESTs deposited in GenBank using the programme
TBLASTN. This search revealed several ESTs, which cor-
responded to the previously reported Smac and some that
contained an alternative prosequence (for example, se-
quence data available from GenBank/EMBL/DDBJ un-
der accession number AA156765) or other sequence
differences. A search of the nonredundant database re-
sulted in the identification of Smac 
 
b
 
, a form of Smac, with
an alternative NH
 
2
 
 terminus (sequence data available
from GenBank/EMBL/DDBJ under accession number
AK001399). Translation of this sequence revealed an ORF
of 186 amino acids that was identical to the reported Smac
molecule in all but the prosequence (Fig. 1, A and B) with
an in-frame stop codon upstream of the initiator methio-
nine, indicating a full-length reading frame (data not 
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shown). Primers were designed to amplify either Smac or
Smac 
 
b
 
 cDNA and were used in reverse transcriptase–
PCR using total RNA isolated from various cell lines as a
template. The mRNA for both Smac and Smac 
 
b
 
 was de-
tected in all the cell lines examined and showed similar ex-
pression levels (Fig. 1 C). To confirm that the Smac 
 
b
 
mRNA was in fact a spliced form of Smac, both the pro-
tein and cDNA sequence of Smac were used to search the
HTGS section of GenBank. These searches revealed a ge-
nomic sequence (sequence data available from GenBank/
EMBL/DDBJ under accession number NT_009438) that
contained regions of identity to Smac and Smac 
 
b
 
 se-
quences, indicative of the exon structure of the gene. The
genomic sequence was composed of sequence from the q
arm of chromosome 12, mapping the 
 
Smac
 
 gene close to
the 
 
APAF1
 
 gene (Kim et al., 1999). From the genomic se-
quence, it was deduced that the 
 
Smac
 
 gene is composed of
seven exons (Fig. 1 A), with the prosequence of Smac en-
coded by exons 1 and 3, and the prosequence of Smac 
 
b
 
encoded by exon 2.
Like many other genes encoding proteins involved in
apoptosis, the 
 
Smac
 
 gene may produce several alterna-
tively spliced forms (Fig. 1 A). As database searching re-
vealed at least three other putative short splice forms of
Smac, we have designated these Smac 
 
b
 
, 
 
g
 
, and 
 
d
 
. Smac 
 
b
 
is identical to the recently described Smac-S (Srinivasula
et al., 2000). Smac 
 
g
 
 (sequence data available from Gen-
Bank/EMBL/DDBJ under accession number BE383154)
should have a similar cellular distribution to Smac 
 
b
 
, due
to the loss of amino acids 18–62 in the mitochondrial-tar-
geting sequence (exon 3) and may bind IAPs only weakly.
Smac 
 
d
 
 (sequence data available from GenBank/EMBL/
DDBJ under accession number AW247557) should be tar-
geted to the mitochondria due to the presence of an intact
targeting sequence (amino acids 1–55) and may bind to the
baculoviral IAP repeat-3 domain of XIAP as amino acids
56–61 are retained. However, Smac 
 
d
 
 lacks amino acids
62–105 due to differential splicing of exon 4 (Fig. 1 B),
probably weakening its binding to XIAP (Chai et al., 2000;
Srinivasula et al., 2000).
 
Smac 
 
b
 
 Localizes to the Cell Cortex
 
Smac and Smac 
 
b
 
 were overexpressed in 293 and MCF-7
cells, and their subcellular localization was determined by
confocal microscopy using an anti-HSV tag antibody (Fig.
2). Smac colocalized with MitoTracker™, indicating a mi-
tochondrial distribution (Fig. 2, A–C). Thus, overex-
pressed Smac showed the same cellular localization as en-
dogenous Smac (Du et al., 2000). In contrast, Smac 
 
b
 
showed a distinct cortical distribution with no mitochon-
drial localization evident (Fig. 2, E–G and I–K). The sub-
cellular localization of Smac 
 
b
 
 was confirmed by fraction-
ation of transfected cells (data not shown). To determine
the effects of both death receptor and chemically medi-
ated apoptosis on the distribution of Smac and Smac 
 
b
 
,
cells were exposed to either TRAIL or etoposide, a DNA
topoisomerase II inhibitor. TRAIL causes a rapid induc-
tion of apoptosis in MCF-7 cells, with caspase-8 as the api-
cal caspase (MacFarlane et al., 2000). Both apoptotic stim-
uli induced the release of Smac from the mitochondria
(Fig. 2 D; data not shown) in agreement with previous re-
ports (Du et al., 2000; Verhagen et al., 2000). In some apop-
totic cells, Smac redistributed to the cell periphery and
displayed a similar distribution to Smac 
 
b
 
. No major
Figure 1. Smac exists as several differ-
entially spliced forms. (A) Schematic
representation of the Smac gene (exons
1–7) and spliced forms encoding
changes in either the mitochondrial-
targeting sequence (MTS) or the IAP-binding site. The noncoding region
is denoted in grey. (B) Alignment of the first 109 amino acids of the four
alternatively spliced forms of Smac. (C) To confirm expression of the
Smac and Smac b spliced forms, reverse transcriptase–PCR was per-
formed (as described in Materials and Methods) on total RNA isolated
from different cell lines using primers specific for either Smac or Smac b. 
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changes in the distribution of Smac 
 
b
 
 were observed in ap-
optotic cells, but it appeared more punctate and accumu-
lated closer to the cell periphery (Fig. 2 H; data not
shown). Thus, in contrast to Smac, Smac 
 
b
 
 showed a dif-
ferent distribution, and its cellular compartmentalization
did not significantly change upon induction of apoptosis.
 
Smac 
 
b
 
 Does Not Interact with IAP Family Members
 
To test whether Smac 
 
b
 
 also interacted with IAPs, lysates
were prepared from transfected 293 cells. Immunoprecipi-
tation of endogenous XIAP demonstrated a strong inter-
action with Smac but little or no interaction with Smac 
 
b
 
(Fig. 3 A, top, lanes 5 and 6), although XIAP was com-
pletely depleted from the lysates (Fig. 3 A, top, lanes 1–3).
Similarly, immunoprecipitation of Smac/Smac 
 
b
 
, which
completely removed Smac/Smac 
 
b
 
 (Fig. 3 B, middle, lanes
2 and 3), confirmed that XIAP interacted with Smac but
not Smac 
 
b
 
 (Fig. 3 B, top, lanes 5 and 6). As Smac 
 
b
 
 was
distributed to the cell periphery, it raised the possibility
that it bound specifically with c-IAP-1 or -2 rather than
with XIAP. Reprobing the blots revealed no interaction of
Smac or Smac 
 
b
 
 with endogenous c-IAP-1 or -2 (Fig. 3 B,
bottom, lanes 5 and 6). Taken together, these data strongly
suggest that the in vivo interaction of Smac with endoge-
nous XIAP is much stronger than with c-IAP-1 or -2 and
that Smac 
 
b
 
 in cells does not interact with endogenous
XIAP or c-IAP-1 or -2.
 
NH
 
2
 
-terminal Processing of Smac 
 
b
 
 in Cells Prevents 
Its Interaction with XIAP
 
The NH
 
2
 
-terminal 55–amino acid residues of Smac are re-
moved upon mitochondrial import, yielding mature 
 
z
 
21-
Figure 2. Smac and Smac b
exhibit a different subcellular
distribution. MCF-7 (A–H)
and 293 (I–K) cells were
transiently transfected with
either Smac (A–D) or Smac
b (E–K) and after 24 h were
fixed and stained for immu-
nofluorescence microscopy
as described in Materials
and Methods. Transfected
cells were stained green
(Alexa 488). Mitochondria
were labeled with Mi-
toTracker™ red CMXRos
(B–D, F–H, and J–L). Cell
nuclei were labeled with
Hoechst 33258 (A–K). Smac
but not Smac b colocalized
with mitochondria (compare
C with G and K). TRAIL
treatment resulted in loss of
Smac from mitochondria of
cells undergoing apoptosis
(indicated by the arrows in
D) and a more punctate dis-
tribution of Smac b (H).
MCF-7 cells transfected with
Smac D60 showed a cortical
distribution (L). Bar, 10 mm. 
Roberts et al.
 
 IAP-independent Potentiation of Apoptosis by Smac
 
225
 
kD Smac. Since Smac 
 
b
 
 has no mitochondrial targeting se-
quence, its predicted molecular weight is 
 
z
 
21.2 kD. Al-
though transiently expressed Smac and Smac 
 
b
 
 should
comigrate on SDS-PAGE since they are similarly tagged,
Smac 
 
b
 
 appeared to be processed intracellularly as it con-
sistently migrated below mature Smac (Fig. 4 A, compare
lanes 2 and 3). To further examine this possibility, the mi-
gration of transiently transfected Smac and Smac 
 
b
 
 was
compared with partially purified recombinant mature
Smac (
 
D
 
55), Smac 
 
b
 
, or Smac 
 
D75 (Fig. 4 A). Transiently
expressed Smac b migrated below both recombinant Smac
D55 and Smac b but similarly to Smac D75. These results
further supported the hypothesis that Smac b was pro-
cessed intracellularly. This processing must have occurred
at the amino terminus, since the protein retained the
COOH-terminal HSV and His6 tags, and Smac b appeared
to be processed z20 amino acids from its NH2 terminus.
Initial experiments to identify this cleavage site were un-
successful because Smac b isolated from cells was NH2-
terminally blocked. Because this NH2-terminal processing
would be predicted to remove the IAP binding domain of
Smac b, we assessed the ability of full-length recombinant
Smac b and Smac D75 to interact with IAPs in an in vitro
interaction assay. Recombinant Smac b but not Smac D75
interacted with XIAP and c-IAP-1 and -2 (Fig. 4 B, com-
pare lanes 3 and 4). Taken together, these data suggest
that the NH2 terminus of Smac b is removed by cellular
processing, therefore explaining its inability to interact
with XIAP in intact cells (Fig. 3, A and B, top, lane 6).
Smac b Potentiates Apoptosis
Processed Smac b may act as a dominant negative inhibi-
tor of apoptosis, since it did not interact with IAPs in in-
tact cells. To test this hypothesis, cells were cotransfected
with constructs for full-length Smac or Smac b together with
the reporter construct pRSC lacZ and then treated with
different apoptotic stimuli, including death receptor stim-
uli (TRAIL and TNF) and etoposide and the proteasome
inhibitor, MG132. In 293 cells, both Smac and Smac b po-
tentiated apoptosis induced by all five apoptotic stimuli
(Fig. 5 A). Similar potentiation was also observed in MCF-7
cells (Fig. 5 B). As Smac b is NH2-terminally processed
to a form, which is unable to interact with IAPs, we pro-
pose that the domain(s) for the proapoptotic function of
Smac b resides in the remaining COOH-terminal frag-
Figure 3. Smac but not Smac b can bind XIAP. Lysates were
prepared from transfected 293 cells. (A) Endogenous XIAP was
immunoprecipitated, and the supernatant and pellet were exam-
ined either for Smac or Smac b using the HSV antibody (top) or
for XIAP using the XIAP antibody (bottom). (B) Lysates were
also incubated with Ni-NTA beads to precipitate His6-tagged
Smac and Smac b and the samples analyzed for XIAP (top) or
Smac and Smac b (middle). The blots were reprobed for c-IAP-1
or -2 (bottom). (C) Expression levels of Smac and Smac b were
measured in the transfected cell lysates. Nonspecific bands detected
by the anti-XIAP antibody (*) and the heavy chain of the antibody
used for immunoprecipitation (‡) are indicated. Occasionally, an
alternative start site in the Smac and Smac b constructs gave rise
to a smaller product (†), which did not interact with IAPs.
Figure 4. Smac b cannot bind XIAP in vivo due to NH2-terminal
processing. (A) 293 cells were transfected with empty vector,
Smac, or Smac b and harvested at 24 h (lanes 1–3), and the mi-
gration on SDS gels of Smac and Smac b was compared with
recombinant Smac D55, Smac D75, and Smac b (lanes 4–6).
(B) 35S IAPs were incubated with beads alone, recombinant
Smac b, or Smac D75 bound to Ni-NTA beads, washed, and
analyzed by autoradiography. (C) Input control showing the
beads bound to Smac b and Smac D75.The Journal of Cell Biology, Volume 153, 2001 226
ment and is independent of IAP interaction. However, it
was formally possible that the NH2-terminal peptide re-
leased, following processing of Smac b, bound to cellular
IAPs, and therefore relieved caspase inhibition when ex-
posed to an apoptotic stimulus. To examine this possibil-
ity, NH2-terminal deletion mutants of Smac, which lacked
the IAP interacting domain, were prepared.
NH2-terminal Truncations of Smac, Lacking IAP 
Binding, Potentiate Apoptosis
The IAP-binding domain of Smac resides in the NH2-ter-
minal amino acids (Chai et al., 2000; Srinivasula et al.,
2000). This was confirmed in the current study; removal of
the NH2-terminal 5 (D60) or 20 (D75) amino acids from
mature Smac resulted in deletion mutants that did not
bind to endogenous XIAP in cells or to recombinant
XIAP in vitro (Fig. 4 B; data not shown). Both of these de-
letion mutants exhibited a similar cortical distribution to
Smac b (Fig. 2 L; data not shown). Deletion of the NH2-
terminal 75 amino acids of Smac resulted in a protein,
which migrated similarly to Smac b in cells, suggesting that
z22 amino acids are removed during the maturation of
Smac b (Fig. 4 A). Most interestingly, both Smac D60 and
D75 potentiated apoptosis to a similar extent as Smac b in
response to different apoptotic stimuli (Fig. 5 C).
Thus, NH2-terminal deletion mutants of Smac, which
are unable to bind XIAP or c-IAP-1 or -2, potentiate ap-
optosis to a similar extent as Smac and Smac b. These data
strongly support the hypothesis that the proapoptotic ac-
tivity of Smac and Smac b is not primarily mediated via re-
lief of the inhibitory action of these specific IAPs. Rather,
we propose that Smac binds XIAP as a secondary function
and that its primary mechanism for promoting apoptosis is
via a domain in the COOH terminus. Because induction of
apoptosis by both death receptor and chemical stimuli was
enhanced, it suggested that Smac and its deletion mutants
may act at a common point where these two apoptotic
pathways converge, possibly at the level of postmitochon-
drial activation of caspases by enhancing the formation or
activation of the apoptosome.
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and the deletion mutants was significantly different (P , 0.05)
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